NCT06439303

Analysis and Evaluation of Smoking Treatment With Cytisine

Analysis and Evaluation of Smoking Treatment With Cytisine: Retrospective Observational Study

• Status: Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 65 (estimated)
• Sponsor: Regina Elena Cancer Institute · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The lack of clinical studies on the use of Cytisine in the treatment of the cessation of smoking, the need to find effective therapeutic alternatives and the opportunity to reduce costs related to the complications of cigarette smoking, represent the main reasons that led to the design of this study.

Detailed description

The study is observational, retrospective and monocentric, and aims to evaluate patients who performed an initial pneumological examination at the Anti-Smoking Center of the National Institute Regina Elena tumors due to smoking cessation in the reference period. To such patients, affected of moderate or severe tobacco use disorder, drug therapy was prescribed with Cytisine 1.5 mg, with the aim of evaluating treatment adherence, efficacy and tolerability of Cytisine as monotherapy in the treatment of moderate or moderate tobacco use disorder serious. Responding patients will be taken into consideration for the study consecutively to the criteria established and pertaining to the Anti-Smoking Center of the National Cancer Institute Regina Elena in the period between 02/01/2023 and 11/30/2023 on first and subsequent visits controls.

Conditions

• Moderate or Severe Tobacco Use Disorder

Interventions

Type	Name	Description
DRUG	Cytisine 1,5 mg	Administration of Cytisine as monotherapy in the treatment of moderate tobacco use disorder or serious

Timeline

• Start date: 2024-03-20
• Primary completion: 2024-06-20
• Completion: 2024-06-20
• First posted: 2024-06-03
• Last updated: 2024-06-03

Locations

1 site across 1 country: Italy